TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04744649
Drug: XELOX or SOX
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: XELOX: Oxaliplatin+Capecitabine; SOX: Oxaliplatin+S-1~Oxaliplatin: 130mg/m2, iv drip for 2h, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: Oxaliplatin Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w~Drug: S1 S-1: 40\~60mg Bid，d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA~JS001: 240mg, ivdrip, d1, q3w;~S-1:40\~60mg Bid, d1\~14, q3w;~Capecitabine: 1000mg/m2 Bid, d1-14, q3w;~Neoadjuvant chemotherapy for 4 cycles, adjuvant chemotherapy for 4 cycles.~Drug: JS001 JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.~Other Name: PD-1 antibody~Drug: Oxaliplatin Oxaliplatin: 130mg/m2,iv drip for 2h, d1, q3w~Drug: S1 S-1: 40\~60mg Bid,d1\~14, q3w~Drug: Capecitabine Capecitabine: 1000mg/m2 Bid, d1-14, q3w Other Name: XELODA
Study: NCT05225610
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml saline will be administered.
Study: NCT06162949
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An antibiotic of macrolide group
Study: NCT05702931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT06575127
Drug: FOLFOXIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: as mentioned in Arm description
Study: NCT05661474
Drug: Fitostimoline ® hydrogel group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of DFUs with Fitostimoline® hydrogel every day for 12 weeks.
Study: NCT05661474
Drug: Saline gauze group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of DFUs with saline gauze every day for 12 weeks.
Study: NCT05729360
Drug: GamCoviMab
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 30 people will be randomized and receive the study drug (GamCoviMab) in a hospital setting (7 days of hospitalization).
Study: NCT06578676
Drug: Ezetimibe/Rosuvastatin 10/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT06578676
Drug: Empagliflozin 25 MG with Ezetimibe/Rosuvastatin 10/10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, QD
Study: NCT05944744
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug doesn't contain any properties or substances for treatment.
Study: NCT05028582
Drug: ARQ-154 Foam 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-154 Foam 0.3%
Study: NCT05028582
Drug: ARQ-154 Vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT05314127
Drug: Fluorouracil Cream
Normalized name: Fluorouracil Cream
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator
Study: NCT05970510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally once a day
Study: NCT05891093
Drug: LHRH agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin acetate, goserelin acetate
Study: NCT06247605
Drug: AL8326 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/tablet, Oral administration, once daily.
Study: NCT06247605
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, once daily.
Study: NCT05597241
Drug: apimostinel
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-methyl-D-aspartate (NMDA) receptor modulator
Study: NCT05597241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06448923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets twice daily
Study: NCT05082259
Drug: ASTX660
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
Study: NCT00136929
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05688839
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses per day, placebo
Study: NCT05901935
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO 1000 mg/m\^2, bid, D1-D14, Q3W
Study: NCT05769738
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4ml of normal saline to be nebulized 3 times daily for 3 days
Study: NCT05027451
Drug: IXT-m200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-methamphetamine chimeric monoclonal antibody (mAb)
Study: NCT05749055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04947007
Drug: Isotonic solution
Normalized name: Isotonic solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, US guided suprascapulary and axillary block will be performed with isotonic solution
Study: NCT04952805
Drug: MAD0004J08
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
Study: NCT06557642
Drug: Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minute inhalation using demand valve and mouthpiece
Study: NCT05160623
Drug: Eyelid cleansing wipes
Normalized name: Systane Lid Wipes Eyelid Cleansing Wipes
Approvals — FDA: no, EMA: no, PMDA: no
Description: EYECARE FORTE eyelid wipes (Dr. Fischer, Israel), used to clean the lids and lashes once daily
Study: NCT06443957
Drug: Intranasal insulin-20U
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
Study: NCT06529445
Drug: Median Dose VC004 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: VC004 Capsules qd per period, for two periods
Study: NCT05872568
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The recommended dose range is 360 to 720mg,bid
Study: NCT04802941
Drug: General practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practice
Study: NCT06167837
Drug: Normal Saline 10 mL Injection
Normalized name: normal saline 10 mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 10 ml IV 30-60 minutes before EGD
Study: NCT04547985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composed of filler material and encapsulated to appear identical to naltrexone.
Study: NCT05748925
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: will be maintained on their medication
Study: NCT03245528
Drug: LJPC-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: angiotensin II
Study: NCT05757479
Drug: Steroid nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 spray into each nostril once a day.
Study: NCT04252625
Drug: Q-Urol
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-Urol is an over-the-counter herbal supplement manufactured by Farr Laboratories. It is a combination product composed of quercetin, pollen extract, bromelain, and papain.
Study: NCT04252625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT04674813
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT04432155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oxygen, and 70% nitrogen
Study: NCT04974060
Drug: Remifentanil Injection
Normalized name: remifentanil Injection
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilute 2mg Remifentanil with normal saline to 50 ml (40ug/ml) and continuously intravenous infused at the doses of 0.02, 0.04, 0.06, and 0.08 μg/kg/min for each lasting 30 minutes.
Study: NCT06149611
Drug: [14C] TQB3616
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.
Study: NCT05517668
Drug: Intravenous infusion of N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomized to Control, the participant will receive only N-acetylcysteine. The dose will be determined by the site investigator. Typical continued infusion rate is 6.25 mg/kg/hr. The control drug (D5W) will be administered using the same schedule as fomepizole.
Study: NCT05613738
Drug: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study: NCT05613738
Drug: 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study: NCT05613738
Drug: 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study: NCT05284318
Drug: Antibiotics treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After receiving intravenous antibiotics treatment for 2 weeks, and clinician determines whether to continue with any antibiotics.
Study: NCT06575829
Drug: Algucosidase alfa 20 mg/kg once every 4 weeks instead of once every 2 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interval of ERT with alglucosidase alfa will be extended from once every 2 weeks to once every 4 weeks. The dose of 20 mg/kg per infusion remains the same.
Study: NCT06181084
Drug: LY3410738
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT06125652
Drug: anti Tim-3/CD123 CAR-T cell therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive prespecified dose of autologous CAR-T cells.
Study: NCT06068673
Drug: Clindamycin 600 mg
Normalized name: clindamycin 600 MG
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin 900 - 1200 mg TWICE per day during 2 weeks period.
Study: NCT06068673
Drug: standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard regimen
Study: NCT06517667
Drug: Icross tear substitute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were instructed to instill 1 drop of 0.20% Cross-linked hyaluronic acid substitute into each eye 3 times per day for 3 months.
Study: NCT00018135
Drug: calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04770220
Drug: Experimental: ALZ-801
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALZ-801 tablet 265 mg BID
Study: NCT04770220
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet BID
Study: NCT05416580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered orally in addition to metformin therapy in the recommended doses in patients with type 2 diabetes mellitus.
Study: NCT04836273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal s.c. self-administration with placebo when blood glucose levels are below 3.9 mmol/L or interstitial glucose levels below 3.5 mmol/L. The frequency of the intervention is approximately once a day.
Study: NCT06044415
Drug: JWH018
Approvals — FDA: no, EMA: no, PMDA: no
Description: A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants
Study: NCT06501378
Drug: PD-1/PD-L1 inhibitor plus chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active brain metastases patients will receive PD-L1/PD-1 inhibitors and chemotherapy.
Study: NCT00117104
Drug: Aranesp®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05424510
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml of Ringer's Lactate
Study: NCT05565729
Drug: LY3471851
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05565729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT06427668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06577233
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10cc of 0.9% normal saline will be injected into the peritoneum overlying the superior hypogastric nerve plexus with a laparoscopic needle during robotic surgery
Study: NCT04751955
Drug: Olinvacimab added to Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Olinvacimab: IV weekly administration In phase lb, 12mg/kg and 16mg/kg weekly IV will be tested. In phase ll, the RP2D in phase lb will be used. Capecitabine: fixed dose as an oral administration, 1250mg/m2 BID on day 1 to 14 followed by 7 days off
Study: NCT06480539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator is a placebo, namely pure saline (NaCl 0.9%), which will be administered following the same regimen as the intervention.
Study: NCT04167033
Drug: Hormone replacement therapy:effect on ventricular repolarization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone replacement therapy and QTc measurement
Study: NCT05276375
Drug: Bronchipret
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchipret syrup (3x 5,4 ml daily) until day 14
Study: NCT06510270
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group
Study: NCT06510270
Drug: Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)
Study: NCT04959981
Drug: ERAS-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05221151
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the night before surgery, 90 minutes before administering the intrathecal anesthesia and 12 hr after surgery
Study: NCT05498441
Drug: Antipsychotics, mood stabilizers, etc.
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the HD-tDCS treatment period, all the participants will maintain the stable medication regimen according to clinical practice guidelines.
Study: NCT06127693
Drug: Tetravalent Influenza Vaccine
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive the tetravalent influenza vaccine
Study: NCT04867642
Drug: UCB0022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.
Study: NCT04431258
Drug: ABTL0812
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABTL0812 will be administered daily at its RP2D. ABTL0812 will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, ABTL0812 will be maintained once chemotherapy is discontinued, if ABTL0812 is tolerated and if the patient is in response or stable disease.
Study: NCT04431258
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX will be dosed according to the standard following regimen:~* oxaliplatin 85 mg/m2, administered as 2-hour iv infusion~* leucovorin 400 mg/m2, administered as 2-hour iv infusion~* irinotecan 180 mg/m2, administered as 1.5-hour iv infusion~* fluorouracil 2400 mg/m2, administered as 46-hour iv infusionevery 2 weeks (=1 cycle) until disease progression or unacceptable toxicities.
Study: NCT04431258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered daily at the same regim as ABTL0812. Placebo will be administered as single agent during a run-in period of one week before starting the first cycle of FOLFIRINOX, then daily during chemotherapy cycles. Also, placebo will be maintained once chemotherapy is discontinued, if the patient is in response or stable disease.
Study: NCT06174766
Drug: HGP2102-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT06174766
Drug: HGP2102-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT06174766
Drug: RLD2209-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug
Study: NCT06174766
Drug: RLD2209-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug
Study: NCT05622474
Drug: Induction chemotherapy plus Concurrent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2，D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles）~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.
Study: NCT05912296
Drug: RBD7022
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered RBD7022 in Healthy Subjects.
Study: NCT05912296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered Placebo in Healthys Subject.
Study: NCT06170476
Drug: HSK21542-60μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK21542 injection of 60 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study: NCT06170476
Drug: HSK21542-120μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK21542 injection of 120 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study: NCT06170476
Drug: HSK21542-180μg
Normalized name: immunoglobulin G, human 180 MG/ML [GamaSTAN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK21542 injection of 180 μg was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study: NCT06170476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo was administered once within 15 min before the end of surgery, and was administered by intravenous bolus injection for no less than 30 s;
Study: NCT05312463
Drug: Tongjiang granule simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongjiang granule simulant,1 bag / time, 3 times / day.
Study: NCT05170048
Drug: EG-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigation drug, EG-301 Tablets 150mg, is for oral use.
Study: NCT03533153
Drug: Conventional drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
Study: NCT06475755
Drug: Immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
Study: NCT04974996
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) infusion
Study: NCT04974996
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT05648201
Drug: Biktarvy 50/200/25 Tab
Normalized name: BIKTARVY 50/200/25 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 single dose of 50/200/25 taken orally
Study: NCT05836350
Drug: 4.8 g/m^2/day NaPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Study: NCT05836350
Drug: 4.8 g/m^2/day placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-week oral administration of 4.8 g/m\^2/day NaPB (in the form of Pheburane) or placebo per day. Although depending on body surface area, \~21 g Pheburane needs to be administered spread over the day in 3 times taken with a meal.
Study: NCT06218940
Drug: HY1272
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive HY1272 weely or HY1272 weely+Oshitinib 80mg P.O. daily
Study: NCT06032195
Drug: Custodiol-N
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: heart will preserved in and will be treated with Custodiol-N solution
Study: NCT06032195
Drug: Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: heart will preserved in and will be treated with Custodiol solution
Study: NCT05550142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution
Study: NCT05136885
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration: Infusion Dose: equivalent weight-based volume as described for trehalose
Study: NCT05020665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally as tablets